Johnson & Johnson Raises Full-Year Outlook Amid Strong Q2 Performance
Johnson & Johnson (JNJ) reported strong fiscal second-quarter results for 2026, with sales rising nearly 7% to $25.31 billion and adjusted earnings per share reaching $2.90—both exceeding analyst expectations. The company raised its full-year revenue guidance to a midpoint of $101.1 billion from previously projected $100.8 billion, signaling confidence in surpassing the $100 billion annual sales milestone for the first time in 140 years. The pharmaceutical segment drove much of this growth with quarterly sales reaching $16.38 billion—above estimates—and new drugs like Tremfya contributing significantly to offsetting losses from patent-expired products such as Stelara, which saw a more than 55% drop in revenue. The company's ability to absorb these declines while still raising guidance has led analysts at Freedom Broker to upgrade JNJ to Buy with an increased price target of $280. However, challenges remain for Johnson & Johnson’s MedTech segment, where sales slightly missed expectations due to inventory pressures and weaker procedure trends in key markets. While the company expects these issues to improve over time, sustained weakness could limit its growth diversification beyond pharmaceuticals.
Tickers: $JNJ
Topics: Earnings Report Healthcare Pharmaceuticals Revenue Growth